Sorry but I don't agree.
Incyte & Merck launched multiple Phase III trials based on promising data from some open-label phase 1/2a trials with a small number of patients. Both companies were overly confident and skipped the mid-stage trials to get a quick approval. That just shows that there is significant risk in not following the standard clinical trial process.
As we know, Viralytics is following a more cautious path with phase 1/2a trials followed by an expansion of cohorts to de-risk the technology prior to phase III registration trials.
The field of immunotherapy combinations in mid/late stage clinical trials has narrowed significantly, so it should encourage Merck, BMS and/or others to lock up anything with such potential as Cavatak. I would think that VLA's long-term insto holders would be talking to Merck about whether the current offer is appropriate in the current competitive landscape. As others have said, it is out of our hands, but I hope to sit back & enjoy the ride.
Just my opinion ...
http://investors.merck.com/news/pre...ostat-and-KEYTRUDA-pembrolizumab/default.aspx
- Forums
- ASX - By Stock
- VLA
- IDO1/Keytruda combo trial fails in melanoma
IDO1/Keytruda combo trial fails in melanoma, page-10
-
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add VLA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online